Health ❯ Healthcare ❯ Medical Treatments
Lung Cancer Multiple Myeloma Glioma Chronic Myeloid Leukemia Small Cell Lung Cancer Desmoid Tumors Prostate Cancer Acute Myeloid Leukemia CAR T-cell Therapy Bladder Cancer Chemotherapy Colorectal Cancer Melanoma Immunotherapy Non-Small Cell Lung Cancer Brain Tumors
The decision follows phase 3 results showing a roughly 14-month median progression-free survival advantage over the THP regimen.